Physician profile
Redentor Roy
NPI 1982674883
$2,546.36
in general payments reported to CMS, 2019-2025
24 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $118 · 2022: $456 · 2023: $719 · 2024: $591 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.35 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $499.91 | 2022-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $398.08 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $185.67 | 2023-2025 | |
| Amgen INC. | $171.77 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $158.01 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $142.01 | 2022-2023 | Krystexxa |
| Travere Therapeutics, INC. | $130.04 | 2023-2025 | |
| Baxter Healthcare | $118.48 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $96.87 | 2022 | |
| Calliditas Therapeutics US INC. | $93.07 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $73.40 | 2023-2024 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $68.09 | 2022-2025 | |
| Genzyme Corporation | $58.99 | 2023 | |
| Ardelyx, INC. | $51.49 | 2023-2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $45.77 | 2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.95 | 2022 | |
| Glaxosmithkline, LLC. | $42.62 | 2025 | Arexvy, Shingrix, Benlysta |
| Scpharmaceuticals INC. | $41.62 | 2025 | |
| Aurinia Pharma U.S., INC. | $29.14 | 2024 | Lupkynis |
| Ascendis Pharma Endocrinology INC | $25.75 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $21.13 | 2025 | |
| Fresenius USA Marketing, INC. | $18.49 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.23 | 2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.78 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Redentor Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.